Press Release Archive
-
Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients
-
New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
-
New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin’s Lymphoma
-
Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma
-
Janssen Submits Application To Ema Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis
-
DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
-
Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL)Preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses
-
Janssen Submits Application to FDA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate to Severe Plaque Psoriasis
-
Phase 3 Study Results Supporting U.S. FDA and European Commission Approvals of STELARA® in the Treatment of Moderately to Severely Active Crohn's Disease Published in The New England Journal of MedicineData from Three Pivotal Phase 3 Studies Detail Efficacy and Safety of First and Only Anti-interleukin-12 and 23 Monoclonal Antibody in Inducing and Maintaining Clinical Response and Remission after ...
-
New Phase 3 Monotherapy Study of Sirukumab Versus Humira® And Sirukumab Data In An Anti-Tnf Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid ArthritisAnti-Interleukin-6 Monoclonal Antibody Sirukumab Efficacy and Safety Findings from SIRROUND-H and SIRROUND-T Trials Presented for the First Time at the 2016 ACR/ARHP Annual Meeting